$TPST
Tempest Therapeutics, Inc. Stock $tpst

$tpst Overview Financials Valuation SEC Filings Company Website

2018 Q2 Form 10-Q Financial Statement

#000154422718000004 Filed on May 03, 2018

Income Statement

Concept	2018 Q2	2018 Q1	2017 Q1
Revenue	$81.00K	$67.00K	$63.00K
YoY Change	-3.57%	6.35%	-56.85%
Cost Of Revenue	$54.00K	$112.0K	$269.0K
YoY Change	-80.29%	-58.36%	-77.13%
Gross Profit	$27.00K	-$45.00K	-$206.0K
YoY Change	-114.21%	-78.16%	-80.0%
Gross Profit Margin	33.33%	-67.16%	-326.98%
Selling, General & Admin	$2.645M	$4.224M	$7.129M
YoY Change	-75.4%	-40.75%	-50.68%
% of Gross Profit	9796.3%
Research & Development	$2.394M	$2.621M	$5.764M
YoY Change	-52.09%	-54.53%	-3.21%
% of Gross Profit	8866.67%
Depreciation & Amortization	$200.0K	$300.0K	$500.0K
YoY Change	-60.0%	-40.0%	-0.79%
% of Gross Profit	740.74%
Operating Expenses	$7.985M	$7.649M	$14.65M
YoY Change	-55.67%	-47.79%	-32.13%
Operating Profit	-$7.904M	-$7.582M	-$14.59M
YoY Change	-55.92%	-48.02%	-31.96%
Interest Expense	$220.0K	$190.0K	-$240.0K
YoY Change	-181.48%	-179.17%	9.09%
% of Operating Profit
Other Income/Expense, Net	-$19.00K	$21.00K	-$60.00K
YoY Change	-176.0%	-135.0%	122.22%
Pretax Income	-$7.703M	-$7.370M	-$14.89M
YoY Change	-57.61%	-50.49%	-31.35%
Income Tax	$0.00	$0.00	$9.000K
% Of Pretax Income
Net Earnings	-$7.703M	-$7.370M	-$14.90M
YoY Change	-57.64%	-50.52%	-31.54%
Net Earnings / Revenue	-9509.88%	-11000.0%	-23642.86%
Basic Earnings Per Share
Diluted Earnings Per Share	-$48.12	-$46.06	-$93.12
COMMON SHARES
Basic Shares Outstanding	35.76M shares	35.73M shares	35.64M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q2	2018 Q1	2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$53.60M	$58.30M	$99.10M
YoY Change	-38.11%	-41.17%	-9.99%
Cash & Equivalents	$24.60M	$19.72M	$25.43M
Short-Term Investments	$29.00M	$38.60M	$73.70M
Other Short-Term Assets	$500.0K	$800.0K	$2.000M
YoY Change	-80.0%	-60.0%	-23.08%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$54.18M	$59.13M	$101.2M
YoY Change	-39.19%	-41.54%	-10.28%
LONG-TERM ASSETS
Property, Plant & Equipment	$403.0K	$2.935M	$4.707M
YoY Change	-89.81%	-37.65%	-45.69%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$142.0K	$146.0K	$0.00
YoY Change			-100.0%
Other Assets	$24.00K	$24.00K	$23.00K
YoY Change	4.35%	4.35%	-94.25%
Total Long-Term Assets	$1.358M	$3.896M	$5.169M
YoY Change	-71.66%	-24.63%	-44.54%
TOTAL ASSETS
Total Short-Term Assets	$54.18M	$59.13M	$101.2M
Total Long-Term Assets	$1.358M	$3.896M	$5.169M
Total Assets	$55.53M	$63.03M	$106.3M
YoY Change	-40.85%	-40.72%	-12.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$757.0K	$1.024M	$2.384M
YoY Change	-76.89%	-57.05%	-43.48%
Accrued Expenses	$3.990M	$4.008M	$8.000K
YoY Change	44233.33%	50000.0%	-99.89%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.747M	$5.032M	$10.59M
YoY Change	-59.84%	-52.49%	-10.3%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$576.0K	$664.0K	$1.006M
YoY Change	-37.73%	-34.0%	-28.14%
Total Long-Term Liabilities	$576.0K	$664.0K	$1.006M
YoY Change	-37.73%	-34.0%	-28.14%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.747M	$5.032M	$10.59M
Total Long-Term Liabilities	$576.0K	$664.0K	$1.006M
Total Liabilities	$5.323M	$5.696M	$11.60M
YoY Change	-58.23%	-50.88%	-12.25%
SHAREHOLDERS EQUITY
Retained Earnings	-$316.6M	-$308.9M	-$265.4M
YoY Change	11.62%	16.37%	39.92%
Common Stock	$36.00K	$36.00K	$36.00K
YoY Change	0.0%	0.0%	33.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$50.21M	$57.33M	$94.72M
YoY Change
Total Liabilities & Shareholders Equity	$55.53M	$63.03M	$106.3M
YoY Change	-40.85%	-40.72%	-12.9%

Cashflow Statement

Concept	2018 Q2	2018 Q1	2017 Q1
OPERATING ACTIVITIES
Net Income	-$7.703M	-$7.370M	-$14.90M
YoY Change	-57.64%	-50.52%	-31.54%
Depreciation, Depletion And Amortization	$200.0K	$300.0K	$500.0K
YoY Change	-60.0%	-40.0%	-0.79%
Cash From Operating Activities	-$4.830M	-$8.934M	-$15.19M
YoY Change	-60.05%	-41.17%	-1.46%
INVESTING ACTIVITIES
Capital Expenditures	$150.0K	$0.00	$75.00K
YoY Change	650.0%	-100.0%	-79.73%
Acquisitions
YoY Change
Other Investing Activities	$9.860M	$12.95M	-$3.240M
YoY Change	-1.4%	-499.69%	-53.52%
Cash From Investing Activities	$9.710M	$12.95M	-$3.312M
YoY Change	-2.61%	-491.12%	-54.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	$0.00	$0.00
YoY Change
NET CHANGE
Cash From Operating Activities	-4.830M	-$8.934M	-$15.19M
Cash From Investing Activities	9.710M	$12.95M	-$3.312M
Cash From Financing Activities	0.000	$0.00	$0.00
Net Change In Cash	4.880M	$4.020M	-$18.50M
YoY Change	-330.19%	-121.73%	-18.68%
FREE CASH FLOW
Cash From Operating Activities	-$4.830M	-$8.934M	-$15.19M
Capital Expenditures	$150.0K	$0.00	$75.00K
Free Cash Flow	-$4.980M	-$8.934M	-$15.26M
YoY Change	-58.88%	-41.45%	-3.3%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q1	dei	Amendment Flag AmendmentFlag	false
CY2018Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2018Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018Q1	dei	Document Period End Date DocumentPeriodEndDate	2018-03-31
CY2018Q1	dei	Document Type DocumentType	10-Q
CY2018Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001544227
CY2018Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	35758907	shares
CY2018Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2018Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2018Q1	dei	Entity Registrant Name EntityRegistrantName	OvaScience, Inc.
CY2017Q4	ovas	Accrued Legal Audit And Tax Services Current AccruedLegalAuditAndTaxServicesCurrent	1542000	USD
CY2018Q1	ovas	Accrued Legal Audit And Tax Services Current AccruedLegalAuditAndTaxServicesCurrent	1647000	USD
CY2017Q4	ovas	Accrued Professional And Consultant Fees Current AccruedProfessionalAndConsultantFeesCurrent	160000	USD
CY2018Q1	ovas	Accrued Professional And Consultant Fees Current AccruedProfessionalAndConsultantFeesCurrent	171000	USD
CY2017Q4	ovas	Development Site Costs And Contract Manufacturing DevelopmentSiteCostsAndContractManufacturing	519000	USD
CY2018Q1	ovas	Development Site Costs And Contract Manufacturing DevelopmentSiteCostsAndContractManufacturing	484000	USD
CY2013Q4	ovas	Ownership Control Percentage With Disputes Resolved Through Arbitration OwnershipControlPercentageWithDisputesResolvedThroughArbitration	0.5
CY2018Q1	ovas	Restructuringand Related Cost Expected Numberof Positions Eliminated Percent RestructuringandRelatedCostExpectedNumberofPositionsEliminatedPercent	0.70
CY2017Q2	ovas	Restructuringand Related Cost Expected Numberof Positions Eliminated Percent RestructuringandRelatedCostExpectedNumberofPositionsEliminatedPercent	0.50
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2242000	USD
CY2018Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1024000	USD
CY2017Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	5562000	USD
CY2018Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	4008000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5562000	USD
CY2018Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4008000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3700000	USD
CY2018Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4030000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-27000	USD
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-31000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	365769000	USD
CY2018Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	366178000	USD
CY2017Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	27000	USD
CY2018Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-35000	USD
CY2017Q4	us-gaap	Assets Assets	72853000	USD
CY2017Q4	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	10	security
CY2018Q1	us-gaap	Assets Assets	63029000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	68781000	USD
CY2018Q1	us-gaap	Assets Current AssetsCurrent	59133000	USD
CY2017Q1	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	500000	USD
CY2018Q1	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	300000	USD
CY2017Q3	us-gaap	Assets Of Disposal Group Including Discontinued Operation AssetsOfDisposalGroupIncludingDiscontinuedOperation	200000	USD
CY2017Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	67203000	USD
CY2018Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	58298000	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2018Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	27000	USD
CY2018Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	30000	USD
CY2017Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	67230000	USD
CY2018Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	58328000	USD
CY2017Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	22900000	USD
CY2018Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	20700000	USD
CY2018Q1	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	10	security
CY2018Q1	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	10	security
CY2017Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	26000	USD
CY2018Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	152000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25433000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15703000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19721000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	58300000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35725230	shares
CY2018Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35758907	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35725230	shares
CY2018Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35758907	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	36000	USD
CY2018Q1	us-gaap	Common Stock Value CommonStockValue	36000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14894000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7374000	USD
CY2017Q1	us-gaap	Cost Of Revenue CostOfRevenue	269000	USD
CY2018Q1	us-gaap	Cost Of Revenue CostOfRevenue	112000	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	461000	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	500000	USD
CY2018Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	330000	USD
CY2018Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	300000	USD
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.42
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2215000	USD
CY2018Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1028000	USD
CY2013Q4	us-gaap	Equity Method Investment Aggregate Cost EquityMethodInvestmentAggregateCost	1500000	USD
CY2013Q4	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.5
CY2017Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	182000	USD
CY2018Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	191000	USD
CY2017Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	38000	USD
CY2017Q4	us-gaap	Equity Method Investments EquityMethodInvestments	146000	USD
CY2018Q1	us-gaap	Equity Method Investments EquityMethodInvestments	146000	USD
CY2017Q3	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	100000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14886000	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7370000	USD
CY2017Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-421000	USD
CY2018Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9000	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	184000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1370000	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-3239000	USD
CY2018Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1641000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-458000	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-743000	USD
CY2018Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	27000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	8555000	USD
CY2018Q1	us-gaap	Liabilities Liabilities	5696000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	72853000	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	63029000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7804000	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	5032000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-18497000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	4020000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3312000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	12954000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15185000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8934000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-14895000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-7370000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	14650000	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	7649000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-14587000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7582000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1126000	USD
CY2018Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	678000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	24000	USD
CY2018Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	24000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-4000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	751000	USD
CY2018Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	664000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-60000	USD
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	21000	USD
CY2018Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	756000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	75000	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2017Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	26562000	USD
CY2018Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	16246000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1578000	USD
CY2018Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	835000	USD
CY2017Q1	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	23325000	USD
CY2018Q1	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	29200000	USD
CY2017Q3	us-gaap	Proceeds From Sale Of Property Held For Sale ProceedsFromSaleOfPropertyHeldForSale	300000	USD
CY2018Q1	us-gaap	Proceeds From Sale Of Property Held For Sale ProceedsFromSaleOfPropertyHeldForSale	200000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6813000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6965000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3113000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2935000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5764000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2621000	USD
CY2017Q1	us-gaap	Restricted Cash RestrictedCash	439000	USD
CY2018Q1	us-gaap	Restricted Cash RestrictedCash	791000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	44369000	USD
CY2017Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	25872000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	16492000	USD
CY2018Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	20512000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	789000	USD
CY2018Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	791000	USD
CY2018Q1	us-gaap	Restructuring And Related Cost Cost Incurred To Date1 RestructuringAndRelatedCostCostIncurredToDate1	9900000	USD
CY2017Q1	us-gaap	Restructuring Charges RestructuringCharges	1488000	USD
CY2018Q1	us-gaap	Restructuring Charges RestructuringCharges	692000	USD
CY2018Q1	us-gaap	Restructuring Charges RestructuringCharges	700000	USD
CY2017Q4	us-gaap	Restructuring Reserve RestructuringReserve	403000	USD
CY2018Q1	us-gaap	Restructuring Reserve RestructuringReserve	451000	USD
CY2018Q1	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	500000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-301480000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-308850000	USD
CY2017Q1	us-gaap	Revenues Revenues	63000	USD
CY2018Q1	us-gaap	Revenues Revenues	67000	USD
CY2017Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7129000	USD
CY2018Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4224000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1360000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	382000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.20
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.70
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.027
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1832250	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1179877	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.58
CY2018Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.96
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2017Q4	us-gaap	Short Term Investments ShortTermInvestments	51500000	USD
CY2018Q1	us-gaap	Short Term Investments ShortTermInvestments	38577000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	64298000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	57333000	USD
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35642000	shares
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35726000	shares
CY2018Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of estimates and summary of significant accounting policies</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These condensed consolidated financial statements are presented in conformity with US GAAP, which requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our significant accounting policies are described in Note 2, “Summary of Significant Accounting Policies,” in our 2017 Annual Report on Form 10-K.</font></div></div>

Files In Submission

Name	View Source	Status
0001544227-18-000004-index-headers.html	Edgar Link	pending
0001544227-18-000004-index.html	Edgar Link	pending
0001544227-18-000004.txt	Edgar Link	pending
0001544227-18-000004-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
ovas-20180331.xml	Edgar Link	completed
ovas-20180331.xsd	Edgar Link	pending
ovas-20180331x10q.htm	Edgar Link	pending
ovas-20180331xex101.htm	Edgar Link	pending
ovas-20180331xex102.htm	Edgar Link	pending
ovas-20180331xex103.htm	Edgar Link	pending
ovas-20180331xex104.htm	Edgar Link	pending
ovas-20180331xex311.htm	Edgar Link	pending
ovas-20180331xex312.htm	Edgar Link	pending
ovas-20180331xex321.htm	Edgar Link	pending
ovas-20180331xex322.htm	Edgar Link	pending
ovas-20180331_cal.xml	Edgar Link	unprocessable
ovas-20180331_def.xml	Edgar Link	unprocessable
ovas-20180331_lab.xml	Edgar Link	unprocessable
ovas-20180331_pre.xml	Edgar Link	unprocessable
ovas20180331ex101image1.gif	Edgar Link	pending
ovas20180331ex104image1.gif	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TPST
Tempest Therapeutics, Inc. Stock $tpst

2018 Q2 Form 10-Q Financial Statement

#000154422718000004 Filed on May 03, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST Tempest Therapeutics, Inc. Stock $tpst

2018 Q2 Form 10-Q Financial Statement

#000154422718000004 Filed on May 03, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST
Tempest Therapeutics, Inc. Stock $tpst